Clinical Trials Browser

Completed × pamiparib × Clear all

Ovarian Neoplasms

NCT05044871 2025-06-08

BRIGHT

Phase 2 Completed

108 enrolled

Gynecologic

Ovarian Neoplasms

NCT03150862 2025-02-04

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Phase 1/2 Completed

116 enrolled 31 charts

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Nervous System Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Gliosarcoma

NCT03333915 2025-02-04

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Phase 1/2 Completed

128 enrolled 36 charts

Breast

Triple Negative Breast Neoplasms

NCT03914742 2025-01-14

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Phase 1/2 Completed

67 enrolled 18 charts

CNS

Glioblastoma

NCT02361723 2024-12-27

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

Phase 1 Completed

101 enrolled

Other solid neoplasm

For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

NCT03150810 2024-12-20

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

139 enrolled 36 charts

BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03427814 2024-10-26

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Phase 2 Completed

136 enrolled 16 charts

Gastrointestinal

Stomach Neoplasms

NCT03575065 2024-10-26

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

Phase 2 Completed

88 enrolled 17 charts

Breast

HER2-negative Breast Cancer

NCT03994211 2024-10-26

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

Phase 1 Completed

25 enrolled 33 charts

Other solid neoplasm

Solid Tumor

NCT04774406 2023-06-06

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Completed

2,336 enrolled

Tumor-Agnostic

Neoplasms

NCT02660034 2021-12-06

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Phase 1 Completed

229 enrolled 46 charts

Other solid neoplasm

Solid Tumors

NCT04774627 2021-09-23

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Completed

200 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

BRIGHT

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Pancytopenia Related to PARP Inhibitors (PancytoRIB)